Diagnostics Industry

Found 4,941 articles

• AccuStem Sciences, Inc. Announces Chairman Purchase of Shares - November 22, 2022

  11/22/2022

  AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market.

• Lung Cancer Screening Dramatically Increases Long-term Survival Rate

  11/22/2022

  Diagnosing early-stage lung cancer with low-dose CT screening drastically improves the long-term survival rate of cancer patients, according to a large-scale, 20-year international study being presented next week at the annual meeting of theRadiological Society of North America.

• Sense and R-Biopharm Nederland B.V. Agree to Distribute Rapid, Instrument-Free Molecular COVID-19 Test in the Netherlands, Belgium, and Luxembourg

  11/22/2022

  Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with R-Biopharm Nederland B.V. for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, point-of-care molecular testing platform.

• Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

  11/21/2022

  Biodesix, Inc. announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of $1.15 per share, including the exercise in full by the underwriter of its option to purchase up to an additional 4,575,000 shares of common stock in the offering.

• Professor László Tabár Joins DetectedX as the Medical Director of Breast Cancer Imaging

  11/21/2022

  DetectedX, leaders in intelligent interactive educational technology, announced that Professor László Tabár, a Nobel Prize Nominee and visionary physician, academic and educator, has joined the company as Medical Director of Breast Cancer Imaging.

• Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer's Disease

  11/21/2022

  Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease, announced key additions to its senior management team.

• Biocept Reports Third Quarter 2022 Financial Results

  11/21/2022

  Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update.

• Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

  11/18/2022

  Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight.

• HIROTSU BIO SCIENCE INC.: World's First Test for Early-Stage Pancreatic Cancer, "N-NOSE® plus Pancreas", Now Available

  11/17/2022

  HIROTSU BIO SCIENCE INC. is pleased to announce the commercialization of "N-NOSE plus Pancreas," the first next-generation "cancer type specific test" for the "N-NOSE®".

• Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director

  11/17/2022

  Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.

• Pathnostics Announces Opening of New Facility in Lake Mary Florida and Expansion of its Irvine California Laboratory and Headquarters

  11/17/2022

  Pathnostics announced the broadening of its diagnostic laboratory capabilities with the opening of its third lab, located in Lake Mary, Florida, and expansion of its Irvine, California-based laboratory and headquarters.

• Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service

  11/17/2022

  Lucira Health, Inc. announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the $29 price of the test, excluding prescription costs.

• International Researchers Poised to Learn New Insights About C2N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference

  11/17/2022

  C2N Diagnostics, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD® blood test, p-tau MAA™ and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer’s disease at the Clinical Trials on Alzheimer's Disease conference.

• Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

  11/17/2022

  Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.

• NeoDynamics Interim Report January-September 2022

  11/17/2022

  Revenues amounted to SEK 151 (339) thousand, of which SEK 73 (24) thousand capitalized costs and SEK 32 (300) thousand net sales, i.e., sales of finished products.

• Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors

  11/17/2022

  Cue Health, a healthcare technology company that puts diagnostic information at the center of care, announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have joined its Board of Directors.

• Biodesix Announces Proposed Public Offering of Common Stock - November 16, 2022

  11/16/2022

  Biodesix, Inc. announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.

• Pictor and Rako Science bring improved access to COVID-19 antibody testing for New Zealand with technology from Tasso

  11/16/2022

  Pictor, a global leader in immunodiagnostics, announced that its PictArray™ SARS-CoV-2 IgG enzyme-linked immunosorbent assay antibody test will soon be available in New Zealand.

• Agilent Announces Cash Dividend of 22.5 Cents Per Share

  11/16/2022

  Agilent Technologies Inc. announced the company has increased its quarterly dividend to 22.5 cents per share of common stock, reflecting a 7% increase over the previous quarter.

• Lunit to Supply AI Platform to Australia's BreastScreen NSW Machine Reading Project

  11/16/2022

  Lunit, a leading medical AI provider serving over 1,000 sites around the world, announced that it has signed a contract to supply its AI solution for the BreastScreen NSW State program, managed by the Cancer Institute NSW.